褪黑素在肌肉骨骼及脊柱相关疾病中的作用:临床前与临床证据的系统综述。
完整摘要 · 中文译文
背景与目的:实验研究表明,褪黑素可能影响与肌肉骨骼退变、修复及部分脊柱相关疾病有关的抗氧化、炎症、线粒体和生物钟通路,但临床转化仍不确定。本系统综述评估了关于外源性母体褪黑素在这些疾病中的体外、动物和人体原始证据。材料与方法:检索了PubMed/MEDLINE和Europe PMC自建库至2026年8月6日的文献;ClinicalTrials.gov另行检索映射。纳入报告为经同行评议的比较性原始研究。一名评价者进行了筛选、数据提取和筛选层面的方法学局限性评估,随后进行了完整的复核一致性检查;未使用自动化工具。在可获取的情况下查阅了全文文章,但获取状态未进行前瞻性记录,无法可靠重建确切获取数量。由于定量合并分析不适用,证据按研究类型和临床领域依据PRISMA 2020和SWiM进行综合。本综述未注册,也未制定独立的研究方案。结果:检索共获得3201条记录,去重后为1646条唯一记录。在437篇进入全文获取和基于现有信息进行报告层面评估的报告中共纳入208篇(23篇体外、142篇动物和43篇人体报告)。临床前研究普遍报告了成骨、软骨保护、抗氧化、抗炎、线粒体和组织修复效应,但研究结果 结果并非一致有利:已有高剂量下骨折重塑受损及MT2依赖性异位骨化的报道。人体证据有限、异质性大,并显示出频繁的筛查层面方法学局限性。制剂、给药途径和暴露量不等效。结论:在所综述的疾病中,褪黑素具有生物学合理性,但临床尚未证实。目前尚无任何一种制剂、剂量或给药途径可被推荐用于疾病修饰、神经功能恢复或组织再生。
完整摘要 · 英文原文
Background and Objectives: Experimental studies suggest that melatonin can influence antioxidant, inflammatory, mitochondrial, and chronobiological pathways relevant to musculoskeletal degeneration, repair, and selected spine-related conditions, but clinical translation remains uncertain. This systematic review evaluated primary in vitro, animal, and human evidence concerning exogenous parent melatonin in these conditions. Materials and Methods: PubMed/MEDLINE and Europe PMC were searched from inception to 6 August 2026; ClinicalTrials.gov was mapped separately. Eligible reports were peer-reviewed comparative primary investigations. One reviewer performed screening, extraction, and a screen-level methodological limitation assessment, followed by a complete consistency pass; no automation tools were used. Complete articles were consulted where accessible, but access status was not logged prospectively and the exact number accessed cannot be reconstructed reliably. Because quantitative pooling was not appropriate, evidence was synthesized by stream and clinical domain according to PRISMA 2020 and SWiM. The review was not registered, and no standalone protocol was prepared. Results: The searches yielded 3201 records and 1646 unique records after deduplication. Of 437 reports taken forward for retrieval and report-level assessment using available information, 208 were included (23 in vitro, 142 animal, and 43 human reports). Preclinical studies generally reported osteogenic, chondroprotective, antioxidant, anti-inflammatory, mitochondrial, and tissue-repair effects, but findings were not uniformly favorable: high-dose fracture-remodeling impairment and MT2-dependent heterotopic ossification were reported. Human evidence was limited, heterogeneous, and showed frequent screen-level methodological limitations. Formulations, routes, and exposures were non-equivalent. Conclusions: Melatonin is biologically plausible but clinically unproven in the reviewed conditions. No formulation, dose, or route can presently be recommended for disease modification, neurological recovery, or tissue regeneration.